科倫藥業(002422.SZ):擬協議受讓辰欣藥業10%的股份
格隆匯7月29日丨科倫藥業(002422.SZ)公佈,公司於2021年7月28日召開第七屆董事會第二次會議,審議通過了《關於公司協議受讓上市公司辰欣藥業股份暨關聯交易的議案》,同意公司與天津乾鼎企業管理合夥企業(有限合夥)(“天津乾鼎”或“轉讓方”)簽訂《股份轉讓協議》,通過股份協議轉讓方式受讓天津乾鼎持有的辰欣藥業股份有限公司(“辰欣藥業”或“標的公司”)4533.53萬股股份及其對應的股東所有權益,佔標的公司目前總股本453,353,000股的10%,轉讓價格為12.8元/股(含税),交易對價總額約5.8億元。
由於天津乾鼎也擬將其所持辰欣藥業6.1015%股份以協議轉讓方式轉讓給公司關聯方石四藥集團有限公司(“石四藥集團”)控制的孫公司即石家莊四藥有限公司(“石四藥有限”),從而石四藥有限也將成為辰欣藥業的股東。根據《深圳證券交易所股票上市規則》及相關規定,此次公司受讓天津乾鼎所持有的辰欣藥業的部分股份將形成公司與石四藥有限均作為辰欣藥業的股東從而導致此次受讓辰欣藥業股份的交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.